Since the first human studies of the mTOR inhibitor Rapamycin to treat astrocytomas in TSC [70], the mTOR inhibitor Everolimus has been licensed by the UK MHRA and US FDA to treat aspects of TSC, including refractory seizures. The gene discussed is MTOR; the disease is tuberous sclerosis.